University of Texas Investment Managment Co. purchased a new stake in shares of Miragen Therapeutics, Inc. (NASDAQ:MGEN) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 105,465 shares of the medical research company’s stock, valued at approximately $1,312,000. Miragen Therapeutics comprises approximately 3.4% of University of Texas Investment Managment Co.’s investment portfolio, making the stock its 11th largest position. University of Texas Investment Managment Co. owned approximately 8.90% of Miragen Therapeutics as of its most recent filing with the SEC.

Shares of Miragen Therapeutics, Inc. (NASDAQ:MGEN) traded up 2.92% during midday trading on Thursday, hitting $11.65. 19,733 shares of the stock traded hands. The company’s market capitalization is $13.81 million. Miragen Therapeutics, Inc. has a 12-month low of $1.80 and a 12-month high of $18.00. The firm’s 50 day moving average price is $12.77 and its 200 day moving average price is $8.36.

ILLEGAL ACTIVITY WARNING: “University of Texas Investment Managment Co. Purchases New Position in Miragen Therapeutics, Inc. (MGEN)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at

Separately, Wedbush restated an “outperform” rating and issued a $19.00 price objective on shares of Miragen Therapeutics in a research note on Monday, April 3rd.

In other news, Director Kyle Lefkoff sold 5,800 shares of the stock in a transaction on Friday, March 10th. The stock was sold at an average price of $14.34, for a total transaction of $83,172.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 36,960 shares of company stock worth $540,110. 26.40% of the stock is currently owned by insiders.

About Miragen Therapeutics

Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.

5 Day Chart for NASDAQ:MGEN

Want to see what other hedge funds are holding MGEN? Visit to get the latest 13F filings and insider trades for Miragen Therapeutics, Inc. (NASDAQ:MGEN).

Receive News & Ratings for Miragen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.